Relationship between serum Prostate Specific Antigen (PSA) in women with polycystic ovary syndrome and some reproductive hormones in Kirkuk city
Article Sidebar
Main Article Content
Abstract
PCOS is one of the most common endocrine disorders among women between 12 and 45 years of age, affecting 5-10% of women. The patients were included in the current study based on the criteria of Rotterdam in the diagnosis of polycystic ovarian syndrome with at least two of the following three criteria: menstrual cycle disorder, chemical criteria for high levels of androgen, detection of polycystic ovary using ultrasound (10 or more cysts of 2-10 mm in diameter). Sixty (60) patients were diagnosed with the syndrome and 30 healthy women were considered as control groups aged between 16 and 46 years.A number of criteria have been adopted to exclude patients who have had previous ovarian surgery as well as women taking contraceptives, steroids and herbal medicines that affect ovarian function for at least two months. The study was conducted at the Azadi Teaching Hospital in the city of Kirkuk for the period from October 2016 to February 2017.
Blood collected for all participants on the second or third day of the menstrual cycle. Body mass index (BMI) was calculated and prostate specific antigen (PSA) level and the level of sex hormones such as Anti-mullarian hormone(AMH),Luteinizing hormone(LH),Follicular stimulating hormone(FSH),Testosterone hormone(T) as well as Luteinizing hormone/Follicular stimulating hormone(LH / FSH) ratio were determined. The relationship between PSA and all studied variables was investigated after dividing the study sample into three age groups A (16-25), B (26-35), and C (36-45) years. Each age group included 30 patients with PCOS and 10 women as a control group).The results showed a significant increase (p <0.05) in the level of the PSA, AMH, LH, T and LH / FSH ratio, conversely the level of FSH was significantly reduced (p <0.05) when comparing women patientswith the control group. Correlation results showed a positive correlation between the PSA level and the values of all the studied variables except for FSH, which was inversely correlated with serum PSA in PCOS patients and for most age groups except for category C where AMH showed a negative correlation with PSA. The results also indicated a significant correlation between PSA and T, LH, and LH / FSH ratio for all ages groups. PSA can therefore be considered as a biochemical marker for androgen activity changes in patients with PCOS
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1-Szczuko, M.; Zapałowska - Chwyc, M.;
Maciejewska, D.; Drozd, A.; Starczewski, A. and
Stachowska, A. (2016).High glycemic index diet in
PCOS patients.The analysis of IGF I and TNF-a
pathways in metabolic disorders. Medical Hypotheses
96 (2016) 42–47.
2-Teede, H.; Deeks, A. and Moran, L.(2010).
Polycystic ovary syndrome: a complex conditions
with psychological, reproductive and metabolic
manifestations that impact on health across the
lifespan. BMC Medicine. 8:41-44.
3-Panda, PK.; Rane, R.; Ravichandran, R.; Singh,
S. and Pancha, H.(2016). Genetics of PCOS: A
systematic bioinformatics approach to unveil the
proteins responsible for PCOS. Genomics Data. 8:52–
60.
4-Macut, D.; Bjekic - Macut, J. and Savic
Radojevic, A. (2013). Dyslipidemia and oxidative
stress in PCOS. Front Horm Res. 40:51–63.
5-Rotterdam ESHRE / ASRM - Sponsored PCOS
consensus workshop group (2004). Revised 2003
consensus on diagnostic criteria and long-term health
risks related to polycystic ovary syndrome (PCOS).
Hum Reprod 19(1):41–47.
6-Zawadzki, J.K. and Dunaif, A. (1992). Diagnostic
criteria for polycystic ovary syndrome: towards a
rational approach. In: DunaifA, Givens JR, Haseltine
F, Merriam GR (eds) polycystic ovarysyndrome.
Blackwell Scientific, Boston, pp 377–384.
7-NIH, National Institute of Health (2012).
Evidence - based methodology workshop on
polycystic ovary syndrome, http://preventionnih. gov/
doc/ programs/ pcos/ Finalreport. pdf. Accessed 18
November 2016.
8-Jamil, A.S.; Alalaf, S.K.; Al-Tawil, N.G. and Al-
Shawaf, T. (2016). Comparison of clinical and
hormonal characteristics among four phenotypes of
polycystic ovary syndrome based on the Rotterdam
criteria. Arch GynecolObstet, 293:447–456.
9-Köninger, A.; Koch, L.; Edimiris, P.; Enekwe,
A.; Nagarajah, J.; Kasimir‑Bauer, S.; Kimmig,
R.; Strowitzki, T. and Schmidt, B. (2014).Anti ‑
Mullerian Hormone: an indicator for the severity of
polycystic ovarian syndrome. Arch GynecolObstet ,
290:1023–1030.
10-Diamandis, E.P.; Yousef, G.M.; Luo, L-Y.;
Magklara, A. and Obiezu, CV. (2000). The New
Human Kallikrein Gene Family: Implications in
Carcinogenesis. TEM, 11(2):54-60.
11-Dash, P.(2015).Reconnoitering the Status of
Prostate Specific Antigen and its Role in Women.
Indian J ClinBiochem. 30(2): 124–13.
12-Friedlander, F.D.; Meyer, P.CH.; Choi, K.;
Cole, P. A.; Hanske, J.; Zavaski, M.; Reznor, G.;
Sun, M.; Kibel, S.A.; Lipsitz, R.S. and Trinh, Q-D
(2017).A nationwide Survey of Prostate Specific
Antigen Based Screening and Counseling for Prostate
Cancer. Urology Practice. 4, 3, 210–217.
13-Tijani KH, C.C.; Anunobi, A.O.; Adeyomoye,
T.O.; Alabi, A.O.; Lawal, N.O. ;Akanmu, R.W.
andOjewola and O.O. Soriyan (2017). The role of
the percentage free PSA in the diagnosis of prostate
cancer in Blacks: Findings in indigenous West
African men using TRUS guided biopsy.African
Journal of Urology. 23(1) 14–19.
14-Littlejohns, J.T.; Travis, C.R. ;Key,J.T. and
Allen, E.N. (2016). Lifestyle factors and prostatespecific
antigen (PSA) testing in UK Biobank:
Implications for epidemiological research.Cancer
Epidemiology. 45: 40-46.
15-Antwi, O.S.; Steck, E. S.; Zhang, H.; Stumm,
L.; Zhang, J.; Hurley, G.T. and Hebert, R.J.
(2015).Plasma carotenoids and tocopherols in relation
to prostate-specific antigen (PSA) levels among men
with biochemical recurrence of prostate cancer.
Cancer Epidemiology. 39 (5) 752-762.
16-Escobar-Morreale, HF.; Serrano-Gotarredona,
J.; Avila, S.; Villar-Palasi, J.; Varela, C. and
Sancho J(1998). The increased circulating prostate
specific antigen concentrations in women with
hirsutism do not respond to acute changes in adrenal
or ovarian function. J ClinEndocrinolMetab, 83:
2580–2584.
17-Gullu, S.; Emral, R.; Asik, M.; Cesur, M. and
Tonyukuk ,V.(2003). Diagnostic value of prostatic
specific antigen in hirsute women. J Endocrinol
Invest. 26(12):1198–202.
18-Mardanian, F. and Hiedar, N.(2011) .Diagnostic
value of prostate-spesific antigen in women with
polycystic ovary syndrome .J Res Med Sci,
16(8):999-1005.
19-Musrap, N .and Diamandis, EP.(2016).Prostate-
Specific Antigen as a Marker of hyperandrogenism in
Women and Its Implications for Antidoping. Clinical
Chemistry, 62(8): DOI: 10.1373/ clinchem. 2016.
256198.
20-Rudnicka, E.; Radowicki, S. and Suchta, K.
(2016). Prostate specific antigen (PSA)in diagnosis of
polycystic ovarian syndrome- anew sight. Journal of
Endocrinology, 32(11):931-935.
21-Hasan, M.M. ; Al-Khayat, TH. and Al-Jeborry;
M.M.(2016). The Relationship between Prostate
Specific Antigen (PSA) and Oxidative Stress in Iraqi
Women with Polycystic Ovary Syndrome (PCOS).
Medical Journal of Babylon Vol. 13- No. 1: 206 -
213.
22-Bahceci, M.; Billge, M.; Tuzcu, A. ;Tuzcu, S.
and Bahceci, S.(2004).Serum prostate specific
antigen level in women with polycystic ovary
syndrome and the effect of flutamide+
desogesttrellethinyl estradiol combination .Journal of
Endocrinological investigation ,27(4). pp: 353-356.
23-Vural, B.; Özken, S. and Bordur, H.(2007). Is
prostate-spesific antigen apotential new marker of
androgen excess in polycystic ovary syndrome?
JObstet Gynaecol Res.33(2):166-173.
24-Quinn, M.; Kao, C.; Ahmad, AK.; Cedars, M.;
Santoro, A.; Eisenberg, E.; Haisenleder, DJ.;
Legro, RS. and Huddleston, H.(2016). Antimullerian
hormone (AMH) as a predictor of
polycystic ovary syndrome (PCOS): age and body
mass index (BMI) - stratified threshold for
distingushing PCOS from controls using an identical
assay. ASRM Abstracts. 106(3) Supplement:e250.
25-Thangavelu, M.; Swaminathan, R.; Krishnan,
V.P.; Gondle, V. Godi, U. and Ravi, M. (2016).
Polycystic ovary syndrome :cause and Applied
sciences, 11(3):159-166.
26-Al-Hakeim, HK.; Jebur, I.M. and Hassoon, S.S.
(2015).Anti-Müllerian hormone in Polycystic Ovary
Syndrome Subgroups.European Journal of Scientific
Research. 131 (3)299 - 309.
27-Mendoça, H.C.; Montenegro, R.M.; Fossa,
C.M.;Silva da Śa, F. M. and Ferriani, A.R. (2004).
Positive correlation of serum leptin with estradiol
level in patient with polycystic ovary syndrome
.Brazillian journal of Medical and Biollogocal
Research, 37:729-736.
28-Rojas, J. Chávez, M.; Olivar, L.; Rojas, M.;
Morillo, J.; Mejas, J.; Calvo, M. and Bermūdez,
V.(2014).ReviowArticl polycystic ovary syndrome,
Insuline Resistance, and obesity: Navigating the
pathophysiologic labyrinth. International Journal of
Reproductive Medicine, Article ID 719050, pp; 17.
29-Rezk, M.; Emarh, M. and Alhalaby, A. (2016).
Anti - Mullerian hormone and luteinizing hormone
for prediction of spontaneous ovulation after
laparoscopic ovarian drilling in clomiphene-resistant
polycystic ovary syndrome. Middle East Fertility
Society Journal. 21: 91–95.
30-Bako, A.U.; Morad, S. and Atiomo, W.A.
(2005). Polycystic ovary syndrome: an overview. Rev
Gynecol Pract.; 5:115–22.
31-Patel, M.; Patel, N. and Singh, N. (2016).Study
Of PCOS And AMH In Infertille Female –European
Journal Of Pharma- Ceutical And Medical Rsearch,
3(5):247-258.
32-Mulders, A.G.; Laven, J.S.; Eijkemans, M.J.;
de Jong, F.H.; Themmen, A.P. and Fauser, B.C.
(2004). Changes in anti-mullerian hormone serum
concentrations over time suggest delayed ovarian
ageing in normogonadotrophicanovulatory infertility.
Hum Reprod. 2004;19:2036–2042.
33-Singer, T.; Barad, D.H. and Weghofer, A.
(2009). Correlation of antimullerian hormone and
baseline follicle-stimulating hormone levels. Fertil
Steril, 91(6):2616–2619.
34-Akram, M. and Roohi, N. (2015). Endocrine
correlates of polycystic ovary syndrome in pakistan
women. Journal of the college of physicians and
surgons Pakistan 25(1):22-26.
35-Murphy, M.K.; Hall, J.E.; Adams, J.M.; Lee,
H. and Welt, C.K. (2006). Polycystic ovarian
morphology in normal women does not predict the
development of polycystic ovary syndrome. J
ClinEndocrinolMetab.91:3878–84.
36-Suganthi, R.; Manonayaki, S. and Benazer,
AFJJ. (2010). Follistatine concentration in women
from kerala with PCO. Iranian journal of
Reproductive Medicine, 8:131-134.
37-Mahmoud, IM.; Habeeb, F. and Kasim, K.
(2015). Reproductive and biochemical changes in
obese and non-obese polycystic ovary syndrome
women.Alexindria Journal of Medicine .51:5-9.
38-Rasqual, R. and Gasimirri, F.(1993).The impact
of obesity on hyperandrogenism and polycystic ovary
syndrome in premenopausal women. Clinical
Endocrinology .Volume 39,no.1 ,pp:1-16.
39-Ganor-Paz, Y.; Friedler Mashiach, Y.; Ghetler,
A.; Hershko Klement, A.; Berkovitz, A.; Gonen,
O.; Shulman, A. and Wiser, A. (2016). What is the
best treatment for women with polycystic ovarian
syndrome and high LH/FSH ratio? A comparison
among in vitro fertilization with GnRHagonist,GnRH
antagonist and in vitro maturation. J Endocrinol
Invest. 39:799–803.
40-Sharquie, K.E.;AL-Bayatti, A.A.; AL-Ajel,
A.L.; AL-Bahar, A.J. and AL-Nuaimy A.A.(2007).
Free Testosterone, Luteinizing hormone/Follicle
Stimulating and pelivicsonography in relation to skin
manifestations in patients with polycystic ovary
syndrome. Sandi Med. J.,28 (7): 1039-43.
41-Dipankar, B.; Kumar, S.M.; Satirath, M. and
Mamata, P. (2005). Clinical correlation with
biochemical staues in polycystic ovarian syndrome.
Jobestet Gynecol India, volu 55(1),pg:67-71.